Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 19/20 | 1.00 |
| ▸ | PIK3CA | P42336 | 17/20 | 1.00 |
| ▸ | MTOR | P42345 | 16/20 | 1.00 |
| ▸ | ATR | Q13535 | 7/20 | 1.00 |
| ▸ | PIK3CD | O00329 | 1/20 | 1.00 |
| ▸ | PIK3CB | P42338 | 1/20 | 1.00 |
| ▸ | PIK3CG | P48736 | 1/20 | 1.00 |
| ▸ | PRKDC | P78527 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17246146 | 1.00 | ATM (1.00) | ATMPIK3CAMTORATRPIK3CD | |
| SCHEMBL30410610 | 1.00 | ATM (1.00) | ATMPIK3CAMTORATRPIK3CD | |
| SCHEMBL17242588 | 0.95 | ATM (1.00) | ATMPIK3CAMTORATRPIK3CD | |
| SCHEMBL17246304 | 0.95 | ATM (1.00) | ATMPIK3CAMTORATRPIK3CD | |
| SCHEMBL17246341 | 0.95 | ATM (1.00) | ATMPIK3CAMTORATRPIK3CD | |
| SCHEMBL19456280 | 0.94 | ATM (0.88) | ATMPIK3CAMTORATRPIK3CD | |
| SCHEMBL17272541 | 0.93 | ATM (1.00) | ATMPIK3CAMTORATRPIK3CD | |
| SCHEMBL20006457 | 0.93 | ATM (0.97) | ATMPIK3CAMTORATRPIK3CD | |
| SCHEMBL22675397 | 0.92 | ATM (0.85) | ATMPIK3CAMTORATRPIK3CD | |
| SCHEMBL17241421 | 0.92 | ATM (1.00) | ATMPIK3CAMTORATRPIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 574 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637720-B2 | Molecular subtyping of small cell lung cancer to predict therapeutic responses | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2026-05-26 | — | — | US | claimed |
| WO-2026104998-A1 | SUBSTITUTED IMIDAZOPYRIDINE COMPOUND DERIVATIVES AND THEIR PHARMACEUTICAL USE | AVELOS THERAPEUTICS INC. (KR) | 2026-05-21 | — | — | WO | claimed |
| WO-2025217307-A9 | METHODS FOR PREDICTING RESPONSE TO A RAS(ON) INHIBITOR AND COMBINATION THERAPIES | Revolution Medicines, Inc. (US) | 2026-05-15 | — | — | WO | claimed |
| EP-4735448-A1 | SUBSTITUTED SPIRO COMPOUND DERIVATIVES AND THEIR PHARMACEUTICAL USE | Avelos Therapeutics Inc. (KR) | 2026-05-06 | — | — | EP | claimed |
| US-20260091123-A1 | COMBINATION OF ANTI-B7-H3 ANTIBODY-DRUG CONJUGATE AND ATR INHIBITOR OR ATM INHIBITOR | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2026-04-02 | — | — | US | claimed |
| EP-4696332-A1 | COMBINATION OF ANTI-B7-H3 ANTIBODY-DRUG CONJUGATE WITH ATR INHIBITOR OR ATM INHIBITOR | Daiichi Sankyo Company, Limited (JP) | 2026-02-18 | — | — | EP | claimed |
| EP-4694939-A1 | PSMA-TARGETED RADIOPHARMACEUTICALS AND DNA DAMAGE RESPONSE INHIBITOR COMBINATION THERAPY | Fusion Pharmaceuticals Inc. (CA) | 2026-02-18 | — | — | EP | claimed |
| EP-4688775-A1 | SUBSTITUTED SULTAM COMPOUND DERIVATIVES AND THEIR PHARMACEUTICAL USE | Avelos Therapeutics Inc. (KR) | 2026-02-11 | — | — | EP | claimed |
| US-20260034120-A1 | TREATING CANCER WITH LONG-ACTING TOPOISOMERASE I INHIBITOR | PROLYNX LLC (US) | 2026-02-05 | — | — | US | claimed |
| US-12466853-B2 | Selective targeting of apoptosis proteins by structurally-stabilized and/or cysteine-reactive NOXA peptides | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2025-11-11 | — | — | US | claimed |
| CN-115398010-A | Biomarkers for Goxatuzumab therapy | 免疫医疗公司 | 2022-11-25 | — | — | CN | claimed |
| WO-2022199547-A1 | 7,9-DIHYDROPURINE DERIVATIVE AND PHARMACEUTICAL PURPOSE THEREOF | 成都赜灵生物医药科技有限公司 | 2022-09-29 | — | — | WO | claimed |
| EP-3807278-B1 | PURINONE DERIVATIVES AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2022-08-31 | — | — | EP | claimed |
| EP-4031181-A2 | METHODS TO IMPROVE PATIENT RESPONSE TO IMMUNE CHECKPOINT INHIBITORS AND FUNCTIONAL TESTS TO PREDICT RESPONSE | Biomarker Strategies, LLC. (US) | 2022-07-27 | — | — | EP | claimed |
| WO-2022155202-A1 | FUSED HETEROCYCLES AND USES OF SAME | SCHRÖDINGER, INC. (US) | 2022-07-21 | — | — | WO | claimed |
| US-20220211783-A1 | GMCI AND DDRI COMBINATION THERAPY FOR TREATING CANCER | TRINITY CAPITAL INC., AS AGENT | 2022-07-07 | — | — | US | claimed |
| US-20220088231-A1 | RADIOIMMUNOCONJUGATES AND DNA DAMAGE AND REPAIR INHIBITOR COMBINATION THERAPY | OXFORD FINANCE LLC | 2022-03-24 | — | — | US | claimed |
| EP-3969050-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | Nuvation Bio Inc. (US) | 2022-03-23 | — | — | EP | claimed |
| WO-2022056111-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | DUKE UNIVERSITY (US) | 2022-03-17 | — | — | WO | claimed |
| EP-3955943-A1 | GMCI AND DDRI COMBINATION THERAPY FOR TREATING CANCER | Candel Therapeutics, Inc. (US) | 2022-02-23 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220088231-A1 | RADIOIMMUNOCONJUGATES AND DNA DAMAGE AND REPAIR INHIBITOR COMBINATION THERAPY | MRE11, DCLRE1A, RAD50 | ATM 56/4885PIK3CA 3082/4885MTOR 4183/4885 |
| US-20260034120-A1 | TREATING CANCER WITH LONG-ACTING TOPOISOMERASE I INHIBITOR | BRCA1, MRE11, TOP1 | ATM 5/4885PIK3CA 134/4885MTOR 2243/4885 |
| US-12466853-B2 | Selective targeting of apoptosis proteins by structurally-stabilized and/or cysteine-reactive NOXA peptides | MCL1, BCL2L1, BCL2L11 | ATM 25/4885PIK3CA 3706/4885MTOR 2648/4885 |
| US-20260091123-A1 | COMBINATION OF ANTI-B7-H3 ANTIBODY-DRUG CONJUGATE AND ATR INHIBITOR OR ATM INHIBITOR | ATR, ATM, ATRIP | ATM 2/4885PIK3CA 1549/4885MTOR 790/4885 |
| US-12637720-B2 | Molecular subtyping of small cell lung cancer to predict therapeutic responses | POU2F1, POU2F2, PARP2 | ATM 166/4885PIK3CA 482/4885MTOR 995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.